M. van den Hauwe

Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials

Eugenio Mercuri, Richard S. Finkel, Jacqueline Montes et al. · Neuromuscular Disorders · 2015 · 212 citations · Full text

Disease Progression, Clinical Epidemiology, Chronic Disease +9

Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial

Gunnar Buyse, Nathalie Goemans, M. van den Hauwe et al. · Neuromuscular Disorders · 2011 · 104 citations

Duchenne Muscular Dystrophy, Clinical Trials, Degenerative Disease +5

Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study

Nathalie Goemans, M. Tulinius, M. van den Hauwe et al. · PLoS ONE · 2016 · 88 citations · Full text

Clinical Variability in Spinal Muscular Atrophy Type <scp>III</scp>

Giorgia Coratti, Sonia Messina, Simona Lucibello et al. · Annals of Neurology · 2020 · 81 citations

Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids

Nathalie Goemans, M. van den Hauwe, Rosamund Wilson et al. · Neuromuscular Disorders · 2013 · 68 citations

Physical Activity, Disease Progression, Daily Corticosteroids +7